Australia Down Classifies Certain IVDs, Gives Labs New Conformity Assessment Route
This article was originally published in Clinica
New rules in Australia have resulted in the down-classification of a small number of IVDs intended to detect certain pathogens and the introduction of an alternative conformity assessment procedure for laboratories that manufacture Class 4 in-house IVDs.
You may also be interested in...
Now that the European Medicines Agency has finalized its formal safety review procedure into Xeljanz, Pfizer is telling health care professionals what precautions they must take when prescribing the drug.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.